Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orialpha (BD-C) Phase I Safety Study in Healthy Volunteers
NCT07300202Phase 1Completed
- Sponsor
- Oriplantee
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Orialpha in breast cancer (5 arms), sponsored by Oriplantee. Primary endpoints: Adverse Events at 7 days, Serious Adverse Events at 7 days and 2 more. Started Feb 2025; status: completed.
02
Drugs
Orialpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07300202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300202.